Mizuho Discusses Biogen (BIIB) Seizure Patient
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen (BIIB) active on headlines
December 9, 2016 1:01 PM ESTBiogen (NASDAQ: BIIB) active on headlines:one patient had treatment-related seizure, loss of pulse.
... More
Biogen (BIIB), AbbVie (ABBV) Receive Health Canada Approve for Once-Monthly Zinbryata
December 9, 2016 8:15 AM ESTHealth Canada has approved ZINBRYTA (daclizumab beta), a new once-monthly, self administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis (RRMS), who have had an inadequate response to, or are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis, Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV)... More
Record-setting rally pushes on as S&P ends week up 3 percent
December 9, 2016 7:20 AM ESTBy Lewis Krauskopf
NEW YORK (Reuters) - Major U.S. stock indexes powered to another day of fresh record highs on Friday, with the S&P 500 ending the week up 3 percent, as investors bid up shares in sectors that have lagged in the month-long rally since Donald Trump's presidential election.
The benchmark S&P 500 registered a record high for the third straight session, while the Dow and Nasdaq also hit new highs. The Dow recorded a fifth straight week of gains.
Trump's expected agenda of economic stimulus and reduced taxes and regulations has particularly fueled financial... More
Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
December 9, 2016 6:34 AM ESTBaird analyst Brian Skorney raised his price target on Biogen (NASDAQ: BIIB) to $309.00 (from $284.00) following additional sola details. The firm stopped short of upgrading the stock, however, and maintained a Neutral rating.
Skorney commented, "Lilly reported additional quantitative results from the Phase 3... More
Biogen (BIIB) Shares Should Trade Higher on CTAD Data - BMO Capital
December 9, 2016 6:29 AM ESTBMO Capital analyst M. Ian Somaiya expects shares of Biogen (NASDAQ: BIIB) to trade higher CTAD data, which show: 1) solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (aducanumab's P3 endpoint); and (2) aducanumab titration yielded efficacy similar to 6-10mg/kg... More
UPDATE: Biogen (BIIB), Biotechs Gain Mid-Day
December 8, 2016 3:03 PM EST(Updated - December 8, 2016 3:07 PM EST)
Biogen (NASDAQ: BIIB), other biotechs gain mid-day. May be related to conference commentary.
UPDATE: The upside is said related to aducanumab data, which was released from embargo earlier. Adam Feuerstein tweeted:
... More
